PASITHEA THERAPEUTICS CORP. Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs
PASITHEA THERAPEUTICS CORP. (KTTA) had Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs of $592.00 thousand as of 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities
us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts · last filed 2023-03-30
- 2022-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $592.00K.
| Period end | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs |
|---|---|
| 2022-12-31 | $592.00K 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Rocket One Inc. (RKTO) | United States | $0.019B |